CSIMarket Company Name, Ticker, Suppliers, else..
 
60 Degrees Pharmaceuticals Inc   (NASDAQ: SXTP)
 
Price: $1.0800 $0.05 4.854%
Day's High: $1.090000033378601 Week Perf: -4.42 %
Day's Low: $ 1.01 30 Day Perf: -7.69 %
Volume (M): 39,935 52 Wk High: $ 8.62
Volume (M$): $ 0 52 Wk Avg: $2.97
Open: $1.03 52 Wk Low: $1.01



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 3
 Employees 3
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Business Description


60 Degrees Pharmaceuticals Inc. is a pharmaceutical company focused on developing products to prevent and treat tropical diseases. They specialize in creating cost-effective solutions for conditions such as malaria, dengue fever, and other illnesses that disproportionately affect people living in tropical regions with limited access to healthcare. The company is dedicated to improving the lives of those affected by these diseases and is committed to increasing global awareness and access to effective treatments.


   Company Address: 1025 Connecticut Avenue Washington 20036 DC
   Company Phone Number: 327-5422   Stock Exchange / Ticker: NASDAQ SXTP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALLR        1.44% 
ATNM   -2.86%    
CUE        10.09% 
HCWB        55.41% 
OPK        0.34% 
TEVA   -5.7%    
• View Complete Report
   



Shares

60 Degrees Pharma Strengthens Fiscal Position Through Strategic $1.043 Million Offering, Paving Way for Future Growth,

Published Wed, Jan 29 2025 1:00 PM UTC

In a strategic move to bolster its financial foundation and support its corporate initiatives, 60 Degrees Pharmaceuticals Inc. (Nasdaq: SXTP) recently announced the culmination of a $1.043 million registered direct offering priced at-the-market under Nasdaq rules. This offering, emblematic of the company s proactive financial strategy, involved issuing common stock and warra...
Shares

60 Degrees Pharma Secures $1.043 Million Through Direct Offering, Elevating Total Year-to-Date Funding to $2.118 Million Amid Strategic Financial Moves,

Published Thu, Jan 30 2025 7:20 PM UTC

60 Degrees Pharma Completes $1.043 Million Registered Direct Offering: A Strategic Move to Enhance Operational FlexibilityIn a significant development for the biotechnology sector, 60 Degrees Pharma (Nasdaq: SXTP) recently announced the successful closing of a registered direct offering that raised approximately $1.043 million. The funds generated from this offering, which ...
Stock Market Announcement

Navigating Market Turbulence: 60 Degrees Pharmas Strategic Funding and Compliance Moves Amidst Research Breakthroughs

Published Thu, Feb 6 2025 7:08 PM UTC

In a decisive move reflecting both resilience and forward-thinking strategy in a challenging market, 60 Degrees Pharmaceuticals has successfully closed a registered direct offering totaling $1.075 million. This significant infusion of capital brings the company’s year-to-date funding total to an impressive $2.118 million. As the pharmaceutical landscape grows increasingly ...
Shares

60 Degrees Pharmaceuticals Initiates Reverse Stock Split to Regain Nasdaq Compliance Amidst Research Advances

Published Thu, Feb 20 2025 3:36 PM UTC

In a strategic maneuver to secure its standing on the Nasdaq exchange, 60 Degrees Pharmaceuticals (SXTP) has announced a 1-for-5 reverse stock split, scheduled to take effect on February 24, 2025. This measure will allow the company to meet Nasdaq’s $1.00 minimum bid price requirement, a crucial compliance threshold for continued listing.The reverse stock split will consol...
Product Service News

Exploring Tafenoquine and Babesia spp 60 Degrees Pharmaceuticals Advances Research in Persistent Babesiosis and Chron...

Published Wed, Jan 8 2025 1:05 PM UTC

In a groundbreaking initiative set to enhance the treatment landscape for persistent babesiosis, 60 Degrees Pharmaceuticals has announced the enrollment of its first patient in a clinical study evaluating tafenoquine. This investigational oral medication, historically utilized for malaria prophylaxis and treatment, is now being studied for its potential to address persistent...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.58
Price to Sales (Expected) -
Price to Book 1.1
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.61
Working Capital Ratio 2.21
Leverage Ratio (MRQ) 0.67
Total Debt to Equity 0.06
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.18 $
Revenues (TTM) 0.42 $
Cash Flow (TTM) 0.85 $
Cash 0.39 $
Book Value 0.99 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 370,331
Net Income per Employee (TTM) -2,703,959
Receivable Turnover Ratio (TTM) 2.13
Inventory Turnover Ratio (TTM) 1.2
Asset Turnover Ratio (TTM) 0.19

Profitability Ratios Current
Gross Margin (MRQ) 27.32 %
Operating Margin (MRQ) -1092.41 %
Net Margin (MRQ) -1089.76 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



60 Degrees Pharmaceuticals Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.